Anthony M. Joshua

Garvan Institute of Medical Research — Australia

Medicine · Health Sciences

70h-index30.6kcitations765works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(324), Cancer Immunotherapy and Biomarkers(159), Radiopharmaceutical Chemistry and Applications(122), Cancer, Lipids, and Metabolism(96), Cancer Genomics and Diagnostics(94)

Publications761 total

Managing Nonfinancial Conflicts of Interest in Oncology Research—A Guide for Practice
JAMA Oncology·2025
Beyond Menopause: Ending the Inequality—Why Men with Prostate Cancer Still Lack Therapies for Hot Flushes
European Urology·2025
Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells
EBioMedicine·2025Open Access
Table 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Table 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Supplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Table 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Figure 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Figure 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Figure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
2025Open Access
Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
2025Open Access
Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer
2025Open Access
1342 First-in-human dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and initial efficacy of mRNA-LNP MT-302 <i>in vivo</i> CAR therapy in solid tumors
2025Open Access
Metformin Active Surveillance Trial in Low-Risk Prostate Cancer
Journal of Clinical Oncology·2025· 1 cited
Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial
European Urology Open Science·2025· 1 citedOpen Access
Real‐world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience
BJUI Compass·2025Open Access
Systemic Surveillance Guidelines for Uveal Melanoma: A Systematic Review
Clinical and Experimental Ophthalmology·2025· 1 citedOpen Access
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Clinical Cancer Research·2025Open Access
1602O Enucleation prevention and vision preservation in primary uveal melanoma (UM): Preliminary results from a phase II study of neoadjuvant darovasertib
Annals of Oncology·2025
page 1 of 39Next →

Frequent Co-authors

Omid Hamid(11), Jedd D. Wolchok(11), Shahneen Sandhu(11), Caroline Robert(10), Adil Daud(10), F. Stephen Hodi(10), Richard Kefford(10), Jeffrey S. Weber(10), Scot Ebbinghaus(10), Antoni Ribas(10), Ian D. Davis(10), Roxana Dronca(9), Amita Patnaik(9), Martin R. Stockler(9), Louise Emmett(9), Peter Hersey(8), Richard W. Joseph(8), Tara C. Gangadhar(8), Hassane M. Zarour(8), Andrew Martin(8)